Tolbutamide
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Tolbutamide
| |
| Systematic (IUPAC) name | |
| 3-butyl-1-(4-methylphenyl)sulfonyl-urea | |
| Identifiers | |
| CAS number | |
| ATC code | A10 V04CA01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H18N2O3S |
| Mol. mass | 270.349 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 96% |
| Metabolism | Hepatic (CYP2C19-mediated) |
| Half life | 4.5 to 6.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral (tablet) |
|
WikiDoc Resources for Tolbutamide | |
|
Articles | |
|---|---|
|
Most recent articles on Tolbutamide Most cited articles on Tolbutamide | |
|
Media | |
|
Powerpoint slides on Tolbutamide | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Tolbutamide at Clinical Trials.gov Clinical Trials on Tolbutamide at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Tolbutamide
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Tolbutamide Discussion groups on Tolbutamide Patient Handouts on Tolbutamide Directions to Hospitals Treating Tolbutamide Risk calculators and risk factors for Tolbutamide
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Tolbutamide | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
For patient information, click here
Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug sold under the brand name Orinase. This drug may be used in the management of type II diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancreas. Since the pancreas must synthesize insulin in order for this drug to work, it is not effective in the management of type I diabetes. It is not routinely used due to a higher incidence of adverse effects compared to newer second generation sulfonylureas, such as glyburide.
Oral antidiabetic drugs and Insulin analogs (A10) | |
|---|---|
| Biguanides | Metformin |
| Sulfonylureas | Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide |
| Alpha-glucosidase inhibitors | Acarbose, Miglitol, Voglibose |
| Thiazolidinediones (TZD) | Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ |
| Meglitinides | Nateglinide, Repaglinide, Mitiglinide |
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin, Linagliptin† |
| Glucagon-like peptide-1 analog | Exenatide, Liraglutide†, Albiglutide† |
| Amylin analog | Pramlintide |
| Insulin analogs | fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir) |
| Dual PPAR agonists | Aleglitazar†, Muraglitazar§, Tesaglitazar§ |
| SGLT2 inhibitor | Dapagliflozin†, Remogliflozin† |
| †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted. | |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
